Yixintang Pharmaceutical Group Co., Ltd.

Equities

002727

CNE100001WJ8

Drug Retailers

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
20.52 CNY -0.58% Intraday chart for Yixintang Pharmaceutical Group Co., Ltd. +1.94% -11.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Yixintang Pharmaceutical's Profit Falls 46% as Revenue Stays Nearly Flat MT
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yixintang Pharmaceutical Group Co., Ltd. completed the acquisition of Assets and Inventories of 10 Stores from Yiliang Yijun Pharmaceutical Co., Ltd. CI
Yunzhong Pharmaceutical Co., Ltd. announced that it expects to receive CNY 20 million in funding from Yixintang Pharmaceutical Group Co., Ltd. and another investor CI
Yixintang Pharmaceutical Group Co., Ltd. agreed to acquire Assets and Inventories of 10 Stores from Yiliang Yijun Pharmaceutical Co., Ltd. for CNY 8.40 million. CI
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Yixintang Pharmaceutical to Buy 43 Stores From Local Peer For 87 Million Yuan MT
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Yixin Convenience Store Chain Co., Ltd. announced that it expects to receive CNY 38 million in funding from Yixintang Pharmaceutical Group Co., Ltd. CI
Yixintang Pharmaceutical Group Co., Ltd. announced a financing transaction CI
Yixintang Pharmaceutical Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 26 May 2023 CI
Yixintang Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2022 CI
Yixintang Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the Year 2022 CI
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
UBS Adjusts Yixintang Pharmaceutical Group's Price Target to 35 Yuan From 51 Yuan, Keeps at Buy MT
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beijing Mulls Banning Internet Healthcare Firms From Selling Drugs Online MT
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Yixintang Pharmaceutical Group Co., Ltd. Proposes Cash Dividend on A Shares for the Year 2021, Payable on April 29, 2022 CI
Yixintang Pharmaceutical Group Co., Ltd. Approves Profit Distribution CI
UBS Adjusts Yixintang Pharmaceutical’s Price Target to 51 Yuan From 56.50 Yuan, Keeps at Buy MT
Yixintang Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2021 CI
Yixintang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Chart Yixintang Pharmaceutical Group Co., Ltd.
More charts
Yixintang Pharmaceutical Group Co., Ltd., formerly Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd., is a China-based company principally engaged in the pharmaceutical chain retailing and pharmaceutical wholesaling businesses. The Company’s main products include traditional Chinese medicines, western medicines, medical equipment, birth control products and disinfection products, among others. The Company distributes its products through regular chain drugstores. The Company mainly operates its business in domestic market, with southwest area of China as its main market.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
20.52 CNY
Average target price
27.74 CNY
Spread / Average Target
+35.19%
Consensus
  1. Stock Market
  2. Equities
  3. 002727 Stock
  4. News Yixintang Pharmaceutical Group Co., Ltd.
  5. Yixintang Pharmaceutical : Pharma to List Over 2 Million Newly Unlocked Restricted Shares